Aim The aim of this study is to highlight the pitfalls in the diagnosis and management of tuberculosis (TB)-associated uveitis. Methods This is a retrospective review of case records of four patients with TB-associated uveitis. Results In cases 1 and 2, failure to treat tubercular uveitis with anti-tubercular therapy (ATT) and unopposed steroid therapy led to a serious systemic consequenceFdevelopment of intra-cranial tuberculoma. In case 4, similar failure to initiate ATT caused recurrent disease (focal choroiditis) in the eye. All four cases showed appearance of new lesions or worsening of existing lesions in the eye, following initiation of ATT. Such paradoxical reactions resolved by adding/increasing corticosteroid therapy. Conclusion TB-associated uveitis needs a strong index of suspicion for diagnosis and a combined anti-tubercular plus anti-inflammatory therapy for successful outcome.
Introduction
Tuberculosis (TB) accounts for a significant proportion of uveitis cases in endemic areas. 1 With the increase in global burden of TB and recognition of newer forms of tubercular uveitis, increasing numbers of patients are likely to be diagnosed of ocular TB. 2 However, the diagnosis of tubercular uveitis is often presumptive, 3 and its management lacks uniform guidelines. We describe four cases that highlight the pitfalls that may occur in the diagnosis and treatment of TB-associated uveitis.
Case 1
A 38-year-old man was diagnosed for intermediate uveitis in the left eye and was treated with periocular and topical steroids. Anti-tubercular therapy (ATT) was not given though his tuberculin reaction was 16 Â 16 mm after 48 h, and other tests were negative. After 7 years, he developed an intra-cranial tuberculoma (Figure 1 ), for which ATT was initiated. After 5 months of ATT, he complained of reduced vision in the left eye. We detected anterior uveitis in the right eye and recurrent intermediate uveitis in the left eye, which we treated with oral and topical prednisolone while continuing ATT. Vitritis reduced significantly and BCVA improved to 20/60 in left eye after 3 months. The cerebral lesion also regressed completely.
Case 2
A 36-year-old woman, presenting with a solitary choroidal granuloma in the left eye (Figure 2a) , was diagnosed as probable ocular sarcoidosis, based on raised serum angiotensin convertase enzyme (SACE) levels, and negative tuberculin test and chest radiography. The lesion regressed well with oral prednisolone (Figure 2b ). After 3 months later, computerised tomography revealed intra-cranial spaceoccupying lesion in her left parietal lobe, diagnosed as intra-cranial tuberculoma ( Figure 2c ). Tuberculin reaction was now 15 Â 15 mm. ATT was started. But 2 weeks later, she developed a chorio-retinitis patch in the left eye, adjacent to the scar of the previous lesion ( Figure 2d ). The lesion subsided with intravenous methyl prednisolone (IVMP, 1 mg/kg for 3 days) followed by oral prednisolone.
Case 3
A 45-year-old man with decreased vision in the left eye (BCVA: 20/80) for 1 month showed serpiginous choroiditis in the left eye ( Figures  3a and b) . Tuberculin test was 23 Â 24 mm, chest radiography was normal and vitreous biopsy was negative for mycobacterial DNA. We started ATT, adding oral prednisolone (1 mg/kg body weight) after 2 days (Figure 3c ). However, after 1 week, BCVA deteriorated to 20/160 in the left eye with clear advancement of choroiditis margins. IVMP (1 mg/kg for 3 days) followed by oral prednisolone led to resolution of lesions.
Case 4
A 24-year-old man presented with extensive pigmentary scarring in the right eye and serpiginous-like choroiditis with focal skip lesions in the left eye (Figures 4a and b) . Tuberculin test was 20 Â 20 mm at 48 h; chest radiograph was normal. We explained the need for starting ATT, but the patient refused fearing side effects of the medication. We treated with IVMP and oral prednisolone, which caused resolution of serpiginous lesions. However, 4 months later, reactivated lesions of serpiginous choroiditis were seen in the left eye (Figure 4c ). Vitreous biopsy detected mycobacterial DNA. The patient agreed for ATT. Oral prednisolone (1 mg/kg body weight) was added after 2 days. But 1 week later, the choroiditis lesions were found enlarged and associated with serous retinal detachment (Figure 4d ). IVMP therapy finally caused resolution of all lesions.
Discussion
These case reports illustrate several pitfalls that may occur in diagnosis and management of TB-associated uveitis. In cases 1 and 2, failure to treat tubercular uveititis with ATT (tuberculin reaction was positive in case 1 and false negative in case 2), along with unopposed steroid therapy, led to a serious adverse systemic consequenceFintra-cranial tuberculoma. In case 4, non-inclusion of ATT during initial therapy Eye (in spite of strong evidence of latent TB) caused recurrent disease in the eye. False-negative tuberculin reaction could occur in poor nutrition and general health, overwhelming acute illness, immunosuppression, or early stages of infection. 4 Interferon-g-release assay could have been useful here. Also, as in case 2, SACE levels could be high in some forms of pulmonary TB. Additionally, a common feature of all the four cases was the appearance of new lesions (cases 1 and 2) or worsening of existing lesions (cases 3 and 4) in the eye, after initiating ATT (Table 1) . Such paradoxical reactions, also called Jarisch-Herxheimer reactions are an established phenomenon in patients with systemic TB, 6, 7 and have also been described for ocular TB. 2, 8 Suggested mechanisms include release of mycobacterial antigens after ATT, strengthening of host's immune response, and decrease in suppressor mechanisms. 6 In cases 3 and 4, however, it may also be argued that inadequate antiinflammatory therapy resulted in worsening of ocular lesions. Rifampicin has been shown to reduce the bio-availability of prednisolone by 66%. 9 In all the four cases, these reactions resolved by adding/increasing corticosteroid therapy.
Tubercular uveitis therefore warrants a strong index of suspicion, and upon diagnosis, a combined anti-tubercular and anti-inflammatory therapy, for successful outcome.
